Unique Ingredient Identifier U725QWY32X is listed as a ingredient substance
| RN | 9003-39-8 |
| NCIT | C82262 |
| RXCUI | 1297406 |
| MF | Polymer substance not supported |
UNII U725QWY32X POVIDONE K30 is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| AURICULAR (OTIC) | SOLUTION, DROPS | 0.2 % |
| BUCCAL | TABLET, EXTENDED RELEASE | 0.5 MG |
| OPHTHALMIC | SOLUTION | 150 MG/1ML |
| OPHTHALMIC | SOLUTION | 2 % |
| OPHTHALMIC | SOLUTION, DROPS | 2 % |
| OPHTHALMIC | SOLUTION, DROPS | 1.8 %W/V |
| OPHTHALMIC | SUSPENSION | 0.6 % |
| ORAL | CAPSULE | 61.5 MG |
| ORAL | CAPSULE (IMMED./COMP. RELEASE), HARD GELATIN | 16 MG |
| ORAL | CAPSULE, COATED, SOFT GELATIN | 5 MG |
| ORAL | CAPSULE, DELAYED ACTION | 12.38 MG |
| ORAL | CAPSULE, DELAYED RELEASE | 8.06 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 82.18 MG |
| ORAL | CAPSULE, SOFT GELATIN | 30 MG |
| ORAL | CAPSULE, SOFT GELATIN LIQUID-FILLED | 25.2 MG |
| ORAL | CAPSULE, SUSTAINED ACTION | 10.05 MG |
| ORAL | CAPSULE, SUSTAINED ACTION, HARD GELATIN | 41.7 MG |
| ORAL | DISPERSIBLE TABLET | 84 MG |
| ORAL | GRANULE | 201.63 MG/1PKT |
| ORAL | GRANULE | 16.4 mg |
| ORAL | GRANULE, EFFERVESCENT | NA |
| ORAL | LIQUID | 30 MG/1ML |
| ORAL | LIQUID,EXTENDED RELEASE | 1.03 MG/ML |
| ORAL | LOZENGE | 35 mg |
| ORAL | PELLET | 3 MG |
| ORAL | POWDER | 18 MG/SACHET |
| ORAL | POWDER FOR ORAL SOLUTION DOSAGE FORM | 5 mg |
| ORAL | POWDER, FOR ORAL SOLUTION | 5 MG |
| ORAL | POWDER, FOR SUSPENSION | 13 MG/5ML |
| ORAL | SOLUTION | 30.5 MG/1ML |
| ORAL | SOLUTION | 5 MG/SACHET |
| ORAL | SUSPENSION | 18.5 MG/5ML |
| ORAL | TABLET | 94 mg |
| ORAL | TABLET (IMMED./COMP. RELEASE), COATED | 8 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 12.5 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 10 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, EFFERVESC | 40 MG |
| ORAL | TABLET, CHEWABLE | 8.18 MG |
| ORAL | TABLET, COATED | 21 MG |
| ORAL | TABLET, CONTROLLED RELEASE | 20.5 MG |
| ORAL | TABLET, DELAYED ACTION | 50 MG |
| ORAL | TABLET, DELAYED ACTION, COATED | 35 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 27.2 MG |
| ORAL | TABLET, DELAYED RELEASE | 40.11 MG |
| ORAL | TABLET, DISPERSIBLE | 3 MG |
| ORAL | TABLET, ENTERIC COATED PARTICLES | 18.6 MG |
| ORAL | TABLET, EXTENDED RELEASE | 90 mg |
| ORAL | TABLET, FILM COATED | 75 MG |
| ORAL | TABLET, MULTILAYER, COATED | 15 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 35.71 MG |
| ORAL | TABLET, SUSTAINED ACTION | 60 MG |
| ORAL | TABLET, SUSTAINED ACTION, COATED | 16 MG |
| SUBLINGUAL | FILM | 2.3 mg |
| SUBLINGUAL | TABLET | 10 MG |
| SUBLINGUAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL | 8 MG |
| TOPICAL | EMULSION, AEROSOL FOAM | 1.9 %W/W |
| TOPICAL | PATCH, CONTROLLED RELEASE | NA |
| TRANSDERMAL | FILM | 5.11 MG |
| TRANSDERMAL | FILM, CONTROLLED RELEASE | 7.27 MG |
| TRANSDERMAL | PATCH | 5.48 mg |
| VAGINAL | TABLET | 50 MG |